{"url_path":"/sec/inm/8-k/2026-04-27/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-048064-index.html","accession_number":"0001213900-26-048064","cik":"0001728328","ticker":"INM","issuer_name":"InMed Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-048064-index.html","primary_entity_key":"0001728328","primary_entity_name":"InMed Pharmaceuticals Inc."},"word_count":98,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits. \n\n \n\n**Exhibit No.**\n \n**Description**\n\n \n \n\n10.1\n \n[Sabby Preferred Investment Option Amending Agreement](ea028772801ex10-1.htm)\n\n10.2\n \n[Form of Wainwright Preferred Investment Option Amending Agreement](ea028772801ex10-2.htm)\n\n99.1\n \n[Press Release](ea028772801ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)\n\n** **\n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nINMED PHARMACEUTICALS INC.\n\n \n \n\nDate: April 27, 2026\nBy:\n/s/ Eric A Adams\n\n \n \nEric A Adams\n\nPresident & CEO\n\n \n\n3"}